EA200801211A1 - Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах - Google Patents

Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах

Info

Publication number
EA200801211A1
EA200801211A1 EA200801211A EA200801211A EA200801211A1 EA 200801211 A1 EA200801211 A1 EA 200801211A1 EA 200801211 A EA200801211 A EA 200801211A EA 200801211 A EA200801211 A EA 200801211A EA 200801211 A1 EA200801211 A1 EA 200801211A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
prostaglandina
chlor
drugs
production
Prior art date
Application number
EA200801211A
Other languages
English (en)
Russian (ru)
Inventor
Вернер Скубалла
Бернд Бухманн
Бернхард Линденталь
Гернот Лангер
Луизелла Тоши
Уилльям Гилфорд
Дарил Фолдс
Джуди Ли
Original Assignee
Байер Шеринг Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Шеринг Фарма Акциенгезельшафт filed Critical Байер Шеринг Фарма Акциенгезельшафт
Publication of EA200801211A1 publication Critical patent/EA200801211A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
EA200801211A 2005-11-21 2006-11-20 Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах EA200801211A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05090321A EP1816121B1 (en) 2005-11-21 2005-11-21 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
PCT/EP2006/011378 WO2007057232A1 (en) 2005-11-21 2006-11-20 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments

Publications (1)

Publication Number Publication Date
EA200801211A1 true EA200801211A1 (ru) 2008-10-30

Family

ID=35744724

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801211A EA200801211A1 (ru) 2005-11-21 2006-11-20 Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах

Country Status (25)

Country Link
EP (1) EP1816121B1 (es)
JP (1) JP2009516665A (es)
KR (1) KR20080068877A (es)
CN (1) CN101312946A (es)
AR (1) AR057900A1 (es)
AT (1) ATE388936T1 (es)
AU (1) AU2006314733A1 (es)
BR (1) BRPI0618756A2 (es)
CA (1) CA2629031A1 (es)
CR (1) CR10006A (es)
DE (1) DE602005005355T2 (es)
DK (1) DK1816121T3 (es)
DO (1) DOP2006000257A (es)
EA (1) EA200801211A1 (es)
EC (1) ECSP088472A (es)
ES (1) ES2302122T3 (es)
GT (1) GT200800066A (es)
IL (1) IL190596A0 (es)
NO (1) NO20082838L (es)
PE (1) PE20070644A1 (es)
PL (1) PL1816121T3 (es)
PT (1) PT1816121E (es)
TW (1) TW200738611A (es)
UY (1) UY29925A1 (es)
WO (1) WO2007057232A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183286B2 (en) 2006-11-16 2012-05-22 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
DE2950027A1 (de) * 1979-12-10 1981-06-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
JP3162668B2 (ja) * 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
JP2000095755A (ja) * 1998-07-21 2000-04-04 Ono Pharmaceut Co Ltd ω―シクロアルキル―プロスタグランジンＥ１誘導体、その製造方法およびその誘導体を有効成分とする医薬組成物
CA2416709A1 (en) * 2000-07-31 2003-01-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for erectile dysfunction containing as the active ingredient prostaglandin derivatives

Also Published As

Publication number Publication date
TW200738611A (en) 2007-10-16
AU2006314733A1 (en) 2007-05-24
BRPI0618756A2 (pt) 2011-09-13
DE602005005355D1 (de) 2008-04-24
CR10006A (es) 2008-07-29
UY29925A1 (es) 2007-06-29
WO2007057232A1 (en) 2007-05-24
CA2629031A1 (en) 2007-05-24
KR20080068877A (ko) 2008-07-24
NO20082838L (no) 2008-06-20
IL190596A0 (en) 2008-11-03
EP1816121A1 (en) 2007-08-08
ES2302122T3 (es) 2008-07-01
DK1816121T3 (da) 2008-06-16
CN101312946A (zh) 2008-11-26
PL1816121T3 (pl) 2008-08-29
DE602005005355T2 (de) 2009-03-26
ECSP088472A (es) 2008-06-30
AR057900A1 (es) 2007-12-26
EP1816121B1 (en) 2008-03-12
PT1816121E (pt) 2008-05-28
PE20070644A1 (es) 2007-07-31
ATE388936T1 (de) 2008-03-15
JP2009516665A (ja) 2009-04-23
DOP2006000257A (es) 2007-06-15
GT200800066A (es) 2009-03-12

Similar Documents

Publication Publication Date Title
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK2029547T3 (da) FXR-agonister
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
EA200702030A1 (ru) Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз